Anavex Life Sciences Corp (AVXL)

[whiskeysausage]

This is it.

I've been quietly sitting in the back row, but load up (or at least buckle up) because several things are going to happen in short succession in the next 90 days that will define the end of 2017 as the official start of Anavex 2-73.

Here are all the indications that 'it' (the success) is about to happen.

Rett trial will start soon. 6 weeks total. 6 weeks data. 6 weeks bureaucracy. The trial will be quick and result-driven. Placebo double blind, double arm, etc. This indicates Dr. M is going for the kill on this one. Results will likely yield fast track. 2-73 to Rett market mid-2018. - Rett will be the thread that undoes the sweater, because 2-73 will then venture into Epilepsy, insomnia, and maybe an array of others.

25% institutional ownership. Much less volatile than the 5% ownership back in CTAD 2015 - this means that when we hit $10, we'll stay at $10. $15. etc.

Money is not a factor in any of this. - Dr. M's financial setup is genius. Between the LPC financing, grants, partnership possibilities, licensing deals, out-right partnerships, money is and will continue to be just fine. Wild card of course is Biogen, then 2nd place Pfizer. Did Anavex license with either of them? No one knows, but if they didn't, someone else will.

My calendar expectations: Rett (mid 2018), Parkinson (end 2018/19), Alz (2019/20), Epilepsy (2019/20) and MS (2020/22). None of these calendar dates are secret to other investors, so as soon as Rett results come in, extrapolation will occur and AVXL will surge again. Keep in mind that each indication on its own is at least a $25-50/share, and money will follow more money.

Given these synergistic variables, I expect Anavex to see $10 by the end of this year, and I expect it to be at $25 by next year.